10-Q: Kraig Biocraft Reports Q3 Loss, Raises Capital

Kraig Biocraft Laboratories, Inc. reported a net loss of $2.84 million for the nine months ended September 30, 2025, while increasing cash reserves through a standby equity purchase agreement.

Summary

• The company reported a net loss of $1,509,566 for the three months ended September 30, 2025, a significant increase from $433,200 for the same period in 2024.
• For the nine months ended September 30, 2025, the net loss was $2,835,732, compared to $2,547,264 for the nine months ended September 30, 2024.
• Operating expenses increased by 238.34% for the three-month period and 12.44% for the nine-month period year-over-year.
• Cash and cash equivalents increased to $1,565,692 as of September 30, 2025, from $673,264 at December 31, 2024.
• The company generated $1,925,702 in proceeds from a Standby Equity Purchase Agreement (SEPA) during the nine months ended September 30, 2025.
• No revenue was generated in either the three or nine months ended September 30, 2025, or 2024.
• A working capital deficiency of $8,544,784 and a stockholders' deficit of $7,956,077 as of September 30, 2025, raise substantial doubt about the company's ability to continue as a going concern.
• The company sold 111 ounces of gold bullion for gross proceeds of $369,992, realizing a gain of $160,896 during the nine months ended September 30, 2025.

Sentiment

Score: 2

Explanation: The company faces severe financial challenges, including increasing losses, no revenue, and a significant going concern warning. While a capital raise provided some liquidity, it is insufficient for long-term operations, and governance issues persist. The long-term potential of its technology is overshadowed by immediate financial instability.

Positives

• Cash and cash equivalents significantly increased to $1,565,692 as of September 30, 2025, from $673,264 at December 31, 2024.
• Successfully raised $1,925,702 through a Standby Equity Purchase Agreement (SEPA) during the nine months ended September 30, 2025, improving liquidity.
• Realized a gain of $160,896 from the partial sale of gold bullion during the nine months ended September 30, 2025.
• Obtained new Investment Registration Certificate and Enterprise Registration Certificate for production operations in Vietnam on January 14, 2025, indicating progress in overseas expansion.

Negatives

• Reported a net loss of $2,835,732 for the nine months ended September 30, 2025, an 11.32% increase from the prior year's loss.
• Operating expenses increased by 12.44% for the nine months ended September 30, 2025, reaching $2,652,125.
• The company continues to have no revenue from its business operations for the reported periods.
• A working capital deficiency of $8,544,784 and a stockholders' deficit of $7,956,077 as of September 30, 2025, indicate significant financial instability.
• Net cash used in operating activities increased slightly to $1,339,483 for the nine months ended September 30, 2025.
• Disclosure controls and procedures were deemed not effective as of September 30, 2025.
• Significant related party liabilities exist, including $1,567,000 in loans from the CEO and $8,004,099 in total accounts payable and accrued expenses to related parties.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to a working capital deficiency of $8,544,784, a stockholders' deficit of $7,956,077, and ongoing cash usage in operations.
• The company has a limited operating history and has not demonstrated the ability to expand its business through increased R&D efforts or achieve commercial success.
• Inability to obtain additional financing on satisfactory terms could prevent the continuation of research, development, and operations, leading to substantial dilution for existing stockholders if equity financing is pursued.
• The company's disclosure controls and procedures were not effective, and internal control weaknesses are not expected to be remediated until commercialization or sufficient cash flow is achieved, posing risks to financial reporting reliability.
• Reliance on genetically engineered silkworms for spider silk production carries inherent risks in the research and development process, including potential product rejection in target markets.
• The company is subject to risks inherent in growing an enterprise, including limited capital resources and business disruptions.

Future Outlook

The company plans to accelerate and expand commercial scale production of its recombinant spider silk, expand research and development for next-generation materials, and create a line of recombinant spider silk fashion wear. It also intends to continue expanding overseas production operations, accelerate microbiology research, develop more advanced fibers, and consider acquiring a revenue-producing company. Additionally, the company will pursue collaborative research and product testing opportunities, seek commercialization partnerships, and actively pursue an uplist to a national exchange if feasible.

Management Comments

• Management acknowledges its responsibility for the preparation of the accompanying unaudited consolidated financial statements which reflect all adjustments, consisting of normal recurring adjustments, considered necessary in its opinion for a fair statement of its consolidated financial position and the consolidated results of its operations for the periods presented.
• Management believes that actions presently being taken to obtain additional funding and implement its strategic plans provide the opportunity for the Company to continue as a going concern.
• Management anticipates that significant additional expenditures will be necessary to develop and expand our business before significant positive operating cash flows can be achieved.
• Management has undertaken steps as part of a plan to improve operations with the goal of sustaining our operations for the next twelve months and beyond. These steps include (a) raising additional capital and/or obtaining financing; (b) controlling overhead and expenses; and (c) executing material sales or research contracts.

Industry Context

Kraig Biocraft Laboratories operates in the niche but potentially high-growth field of advanced biomaterials, specifically recombinant spider silk. This technology aims to disrupt traditional textile and specialty fiber industries by offering materials with superior strength, resiliency, and flexibility, potentially replacing petrochemical-based inputs. The company's focus on 'green' fibers aligns with increasing global demand for sustainable and environmentally friendly materials. However, the industry is highly research-intensive, with significant upfront investment and long development cycles before commercialization, which is reflected in the company's current lack of revenue and ongoing losses. Competition in advanced materials and biotechnology is intense, requiring continuous innovation and substantial capital.

Comparison to Industry Standards

• The company's lack of revenue and consistent net losses are below industry standards for established commercial entities in the textile or specialty fiber sectors, which typically demonstrate revenue generation and profitability.
• Compared to early-stage biotechnology or advanced materials startups, the company's prolonged period without commercial revenue, coupled with a significant accumulated deficit of $55,921,451, suggests a slower-than-average progression towards market viability or a more capital-intensive development path.
• The reliance on related-party loans and the continuous need for equity financing, as evidenced by the SEPA, indicates a funding model more typical of pre-revenue startups rather than companies nearing commercial scale production.
• The stated ineffectiveness of disclosure controls and procedures is a significant governance weakness, falling below the expected standards for publicly traded companies, regardless of size or industry.

Corporate Governance

Legal Proceedings

• The company may be involved in legal actions and claims arising in the ordinary course of business, but none are currently considered material to the company's business or financial condition.

Related Party Transactions

• The company owes $1,567,000 to its founder and CEO in outstanding loans as of September 30, 2025.
• Accrued salary balance owed to the CEO is $4,205,136 as of September 30, 2025.
• Total accounts payable and accrued expenses to related parties, including accrued salaries and interest, amounted to $8,004,099 as of September 30, 2025.
• The company owes $65,292 in royalty agreement payable to the Chief Executive Officer as of September 30, 2025.
• During the nine months ended September 30, 2025, the company recorded $60,472 as an in-kind contribution of interest related to the loan from the CEO.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from ongoing equity sales under the SEPA and potential future capital raises. The going concern warning indicates a high risk of capital loss. Ineffective disclosure controls may limit transparency.
• **Employees:** Accrued salaries, particularly for senior staff, indicate potential payment delays or non-payment, which could impact morale and retention.
• **Creditors:** Related party creditors, including the CEO, hold substantial outstanding loans and accrued interest, posing a risk if the company cannot improve its financial position.
• **Customers/Partners:** Potential future customers or partners may be hesitant due to the company's financial instability and going concern warning, despite the promising technology.

Next Steps

• Accelerate and expand commercial scale production of recombinant spider silk.
• Expand research and development to create next-generation materials and improve existing recombinant spider silk lines.
• Create a line of recombinant spider silk fashion wear, either under its own brand or in partnership with existing commercial entities.
• Continue the expansion of overseas production operations, including working with local contractors or cooperatives and hiring additional direct staff.
• Accelerate microbiology research and development to create more advanced materials.
• Develop more advanced spider silk and non-spider silk based fibers for select target markets.
• Consider buying an established revenue-producing company in a compatible business to broaden its financial base and facilitate commercialization.
• Actively pursue collaborative research opportunities with private laboratories.
• Actively pursue collaborative research and product testing opportunities with companies in the biotechnology, materials, and textile industries.
• Actively pursue additional collaborative commercialization, marketing, and manufacturing opportunities.
• Actively pursue an uplist to a national exchange if such an opportunity presents itself.
• Work on establishing and maintaining effective disclosure controls and procedures.

Key Dates

Recommendation

The company's financial position is highly precarious, marked by increasing net losses, zero revenue, a substantial accumulated deficit, and an explicit 'going concern' warning. While recent capital raises provide temporary liquidity, they are insufficient to address the underlying operational cash burn and long-term funding needs. The ineffectiveness of disclosure controls and internal control weaknesses further compound the risks. The significant related-party liabilities also raise governance concerns. Without a clear path to revenue generation and profitability, the investment carries extreme risk, making it unsuitable for most investors.

Keywords

spider silk, biotechnology, recombinant DNA, textile industry, specialty fiber, technical textiles, silkworms, SEC filing, 10-Q, financial results, going concern, capital raise, research and development, Vietnam operations